1. Home
  2. MAIN vs VKTX Comparison

MAIN vs VKTX Comparison

Compare MAIN & VKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MAIN
  • VKTX
  • Stock Information
  • Founded
  • MAIN 2007
  • VKTX 2012
  • Country
  • MAIN United States
  • VKTX United States
  • Employees
  • MAIN N/A
  • VKTX N/A
  • Industry
  • MAIN Finance/Investors Services
  • VKTX Biotechnology: Pharmaceutical Preparations
  • Sector
  • MAIN Finance
  • VKTX Health Care
  • Exchange
  • MAIN Nasdaq
  • VKTX Nasdaq
  • Market Cap
  • MAIN 4.5B
  • VKTX 4.7B
  • IPO Year
  • MAIN 2007
  • VKTX 2015
  • Fundamental
  • Price
  • MAIN $60.02
  • VKTX $32.65
  • Analyst Decision
  • MAIN Hold
  • VKTX Strong Buy
  • Analyst Count
  • MAIN 5
  • VKTX 12
  • Target Price
  • MAIN $48.80
  • VKTX $106.75
  • AVG Volume (30 Days)
  • MAIN 563.7K
  • VKTX 4.1M
  • Earning Date
  • MAIN 02-27-2025
  • VKTX 02-05-2025
  • Dividend Yield
  • MAIN 7.00%
  • VKTX N/A
  • EPS Growth
  • MAIN 11.78
  • VKTX N/A
  • EPS
  • MAIN 5.51
  • VKTX N/A
  • Revenue
  • MAIN $529,897,000.00
  • VKTX N/A
  • Revenue This Year
  • MAIN $10.58
  • VKTX N/A
  • Revenue Next Year
  • MAIN $5.22
  • VKTX N/A
  • P/E Ratio
  • MAIN $10.90
  • VKTX N/A
  • Revenue Growth
  • MAIN 9.27
  • VKTX N/A
  • 52 Week Low
  • MAIN $43.78
  • VKTX $20.75
  • 52 Week High
  • MAIN $60.87
  • VKTX $99.41
  • Technical
  • Relative Strength Index (RSI)
  • MAIN 69.24
  • VKTX 25.74
  • Support Level
  • MAIN $57.05
  • VKTX $32.51
  • Resistance Level
  • MAIN $60.19
  • VKTX $43.55
  • Average True Range (ATR)
  • MAIN 0.96
  • VKTX 2.05
  • MACD
  • MAIN 0.05
  • VKTX -0.44
  • Stochastic Oscillator
  • MAIN 77.80
  • VKTX 1.27

About MAIN Main Street Capital Corporation

Main Street Capital Corp is an investment firm engaged in providing customized debt and equity financing to lower middle market companies and debt capital to middle market companies. The investment portfolio of the company is typically made to support management buyouts, recapitalizations, growth financings, refinancing's, and acquisitions of companies that operate in diverse industry sectors. The group invests in secured debt investments, equity investments, warrants, and other securities of the lower middle market and middle market companies based in the United States. Business functioned through the U.S. region and it derives the majority of its income from the source of fees, commission, and interest.

About VKTX Viking Therapeutics Inc.

Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.

Share on Social Networks: